Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZYIL1 in Cryopyrin Associated Periodic Syndromes (CAPS)
NCT05186051Phase 2Completed
- Sponsor
- Zydus Lifesciences Limited
- Start
- Jun 2022
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of usnoflast in Cryopyrin-associated periodic syndromes (CAPS), sponsored by Zydus Lifesciences Limited. Primary endpoint: Incidence and Severity of Adverse event of ZYIL1 at Day 7. Started Jun 2022; status: completed.
02
Drugs
usnoflast
03
Conditions
Cryopyrin-associated periodic syndromes (CAPS)
Beyond the preview
Go deeper on NCT05186051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05186051.